We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 103.00 | 102.00 | 104.00 | 104.00 | 103.00 | 103.00 | 14,948 | 08:00:02 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
From Apr 2019 to Apr 2024
TIDMDXRX
RNS Number : 7125E
Diaceutics PLC
08 July 2019
8 July 2019
Diaceutics PLC
("Diaceutics" or the "Company")
Trading update
Diaceutics PLC (AIM: DXRX), a provider of data analytics and implementation services to the global pharmaceutical industry, announces a trading update for the six months ended 30 June 2019. Trading has continued in line with market expectations and the Company remains well positioned in key markets, underpinned by a strong sales performance.
An increased international footprint has enhanced Diaceutics' global offering and allowed the Company to acquire new international clients. The Nexus project is progressing as planned.
All outstanding debt has now been retired from the balance sheet resulting in net cash of GBP14.0m.
The Group's interim results are expected to be announced in early September.
Enquiries:
Diaceutics PLC www.diaceutics.com Peter Keeling, Chief Executive via Walbrook PR Officer Philip White, Chief Financial Officer Cenkos Securities plc (Nominated adviser and broker) +44 (0) 20 3861 6630 Callum Davidson / Giles Balleny Michael Johnson (Sales) Walbrook PR Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com Anna Dunphy Mob: +44 (0)7876 741 001 Paul McManus Mob: +44 (0)7980 541 893
About Diaceutics
Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
TSTUGUQAMUPBURQ
(END) Dow Jones Newswires
July 08, 2019 02:00 ET (06:00 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
